Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986482 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BMS-986482 (Nov 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986482 | BMS986482|BMS 986482 | Limited information is currently available on BMS-986482 (Nov 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06697197 | Phase Ib/II | BMS-986482 + Nivolumab and relatlimab-rmbw Bevacizumab + BMS-986482 BMS-986482 BMS-986298 + BMS-986482 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | ITA | GRC | FRA | ESP | DNK | BEL | 0 |